Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.

Tsung-Hua ShenElizabeth S AbyDavid VockJoel F Farley

Published in: Diabetes, obesity & metabolism (2024)

In patients with T2D and MASLD, SGLT2is did not show a lower risk of MLO compared with DPP4is. Clinicians should consider the overall patient conditions and the additional benefits of SGLT2is to support the decision to switch from DPP4is.

Keyphrases

case report
oxidative stress
palliative care
decision making
type diabetes
weight loss